SAN DIEGO, January 11, 2022 – Meet Antonius Schuh, Ph.D. (CEO), Andreas Klostermann, Ph.D. (CSO) and Steve Zaniboni (CFO) for an update on selectION’s best-in-class ion channel blockers and the status of the clinical work.
Site Search
Recent News
- selectION Announces Positive Results from Phase 1b Clinical Trial Evaluating si-544 in Patients with Atopic Dermatitis
- Meet selectION, Inc. at the Global Life Science Partnering & Investor Conference in La Jolla, CA, on February 27th to 29th, 2024
- selectION, Inc. to Present Update on Clinical Progress at the 42ndAnnual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 11, 2024